Cluenex
Log inStart free
All stocks · Healthcare · Clinical Research Services

Medpace MEDP

Medpace scores excellent on business quality (8.5 of 10). Here is why, in plain words, and what our sealed record shows.

Last price$612.05Oct 9, 2026
Business qualityExcellent
Next earningsOct 21, 2026, after the close
Insiders, 90 daysSelling

Why it matters

  1. What Medpace does

    Medpace Holdings provides full-service clinical development outsourcing to pharmaceutical and biotechnology firms, managing trials from early-stage to regulatory approval.

  2. What it does best

    Medpace executes complex clinical trials for mid-sized biotech clients with a disciplined full-service model that drives an exceptional ROE of 110.1%: far outpacing peers like IQVIA at 22.0% and Waters at 18.5%.

  3. The main risk

    Insiders hold significant influence, highlighted by the CEO trading $30.32M in company stock, which introduces potential management alignment questions if clinical execution slips or client pipelines contract.

Quality, check by check

Scored against its own industry, from company filings.

ProfitabilityStrong

Operating margins sit at 21.0% with free cash flow conversion near $707M, proving that scale directly improves operational efficiency.

MoatStrong

Client switching costs anchor its moat, supported by an ROE in the top decile of its sector at 94th percentile, locking in drug developers for multi-year trials.

GrowthFast

Revenue growth reached 20.0%, accelerating from historical years like 2021 as demand for outsourced trial management steadily expands.

Financial healthStrong

Zero long-term debt and $497M in cash back a pristine balance sheet, fueling $707M in free cash flow: financial health is elite.

Insiders

Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.

7 sold $208.5M outside pre-planned sales.

Our sealed record on MEDP

Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.

The first sealed verdicts appear here on Oct 11, 2026.

Questions

Is MEDP a good business?

Medpace scores excellent on the Cluenex quality check (8.5 of 10), measured against its own industry. Profitability is strong, moat strong, growth fast and financial health strong.

Are insiders buying MEDP?

In the last 90 days of SEC Form 4 filings: 7 sold $208.5M outside pre-planned sales.

When does MEDP report earnings?

Oct 21, 2026, after the close.

For members

See MEDP today

  • Today's verdict on MEDP, and why
  • Fair value with cautious, base and optimistic cases
  • The exact price that would change the verdict
  • Which stocks each signal names, the night it fires
Open in Cluenex Free to start. First month of Core free.

Cite this page: Cluenex, “Medpace (MEDP)”, https://cluenex.com/stocks/medp/, data as of Oct 10, 2026.